Figure 4 3,4-Difluorobenzocurcumin inhibits pathological phenotypes associated with vegfc overexpression. (A?G?) Lateral confocal images of either a 3 dpf Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP);Tg(fli1a:nEGFP) larva (Non-vegfc-induced) treated with 0.1% DMSO (A,A?), or 3 dpf Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP);Tg(10XUAS:vegfc);Tg(fli1a:nEGFP) larvae (vegfc-induced) treated with either 0.1% DMSO (B,B?), 4 ?M SL327 (C,C?), 20 ?M sunitinib malate (SM, D,D?), 10 ?M curcumin (CM, E,E?), 2,5 ?M 3,4-Difluorobenzocurcumin (CDF, F,F?), or 5 ?M CDF (G,G?). Pathological vascular phenotypes in vegfc-induced embryos are rescued by CDF treatment. Images (A??G?) represent the Tg(prox1a:KALTA4,4xUAS-E1B:TagRFP) expression of images (A?G). To avoid the robust prox1a expression in muscle cells, (A??G?) are maximum projection images of only the z stacks that contain the posterior cardinal vein. Images (B?) (21/22 embryos), (E?) (23/23 embryos) and (F?) (14/20 embryos) show embryos with increased prox1a:KALTA4,4xUAS-E1B:TagRFP expression in venous endothelial cells. This pathological phenotype is rescued in images (C?) (20/20 embryos), (D?) (27/27 embryos) and (G?) (21/24 embryos). (H) Quantification of fli1a:EGFP-positive ECs across 4.5 somites in either 3 dpf non-vegfc-induced treated with 0.1% DMSO (n = 21 embryos) or 3 dpf vegfc-induced larvae treated with either 0.1% DMSO (n = 22 embryos), 4 ?M SL327 (n = 20 embryos), 20 ?M SM (n = 27 embryos), 10 ?M CM (n = 23 embryos), or CDF at 2.5 ?M (n = 20 embryos) or 5 ?M (n = 24 embryos). PCV: posterior cardinal vein. Statistical test: Kruskal-Wallis test was conducted for graph H. p ? 0.001 (***) and n.s. indicates not significant. Scale bar: 100 ?m.
Image
Figure Caption
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Pharmaceuticals (Basel)